Lucia Bio develops oral small molecule inhibitors targeting spleen tyrosine kinase (Syk) for therapeutic intervention in immunology, neurology, and hematology/oncology. Their inhibitors offer high potency and selectivity, designed with optimized drug-like properties to address unmet medical needs.
Funding
$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Targeting spleen tyrosine kinase (Syk) and its dependent pathways for therapeutic intervention in complex diseases remains a significant challenge. Developing small molecule inhibitors with the requisite potency, selectivity, and drug-like properties for clinical advancement requires specialized expertise in medicinal chemistry and pathway biology.
Solution
Lucia Bio is developing a portfolio of oral small molecule inhibitors targeting spleen tyrosine kinase (Syk). These inhibitors are designed for high potency and selectivity, addressing a clinically validated node implicated in peripheral immunology, neurology, and hematology/oncology indications. The company leverages deep knowledge of Syk and its downstream signaling pathways to engineer molecules with optimized pharmacokinetic and pharmacodynamic profiles. This approach aims to facilitate the progression of these novel therapeutics into clinical development for a range of unmet medical needs.
Target Audience
Lucia Bio's primary customers are pharmaceutical and biotechnology companies seeking to license or co-develop novel therapeutics for indications involving Syk-mediated signaling.
Features
- Oral small molecule inhibitors targeting Spleen Tyrosine Kinase (Syk).
- High potency and selectivity profiles for targeted therapeutic intervention.
- Tailored drug-like properties for enhanced pharmacokinetic and pharmacodynamic performance.
- Focus on peripheral immunology, neurology, and hematology/oncology applications.
- Proprietary discovery and development platform for Syk inhibitors.